Nishmitha Puchakayala

Nishmitha Puchakayala

Auto-generated profile, based on publicly available information

Nishmitha Puchakayala

Osmania Medical College, Hyderabad, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
ASArkansh Sharma
Arkansh Sharma
RRRishu Raj
Rishu Raj
MAMohammad Orooj Azmi
Mohammad Orooj Azmi
NPNishmitha Puchakayala
Nishmitha Puchakayala
AKAnmol Kaur
Anmol Kaur
OUOlivier Uwishema
Olivier Uwishema
Background: Sleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear. Objective: To compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs). Methods: Following PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges’ g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis. Results: Twelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD −1.09) and WASO (SMD −0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD −0.98), with favorable short-term tolerability. Walking (SMD −0.48), bright light therapy (SMD −0.37), and NITE-AD (SMD −0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD −0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects. Conclusions: Non-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.